2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV, GSK), administered to adults ≥ 50 years of age (YOA) demonstrated ≥ 90% efficacy against herpes zoster across all age cohorts. Vaccine-specific immune responses elicited by two RZV doses in adults ≥ 60 YOA have been shown to persist above p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Bastidas, Adriana, Catteau, Grégory, Volpe, Stéphanie, Mrkvan, Tomas, Enemuo, Adaora, Smetana, Jan, Schwarz, Tino, Rombo, Lars, Pauksens, Karlis, Berengier, Estelle, Hervé, Caroline, Oostvogels, Lidia, Schuind, Anne
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808880/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.183
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados